Table 1—

Platelet function in type 1 and type 2 diabetes and IR

Platelet responseIRType 1 diabetesType 2 diabetes
Antiaggregatory activity of insulin (human platelets)↓(42, 62)↓(42)
Antiaggregatory activity of NO (human platelets)↓(43)↓(43)
Antiaggregatory activity of prostacyclin (human platelets)↓(62)↓(63)
cGMP response to NO (human platelets)↓(44)↓(45)↓(44, 49)
cNOS activity (human platelets)↓(46, 47)↓(46, 47)
iNOS activity (human platelets)↑(48)↑(48)
Prostacyclin binding (human platelets)→ (38)→ (38)
Antiaggregatory activity of HDL (streptozotocin rat model)↓(50)
Thrombin-induced PI hydrolysis (human platelets)↓(41)↑(52–54)
Thrombin-induced PI hydrolysis (streptozotocin rat model)↑(51)
Thromboxane synthesis (human platelets)↑(55)↑(57)
Thromboxane receptor sensitivity (human platelets)↑(56)
Arachidonic acid uptake (human platelets and streptozotocin rat model)↑(58)
Aggregation in response to LDL (human platelets)↑(59, 61)
Release of PAI-1 (human platelets)↑(60)
  • ↓, Decreased; ↑, increased; →, no change. Reference numbers are given in parentheses. NOS, constitutive nitric oxide synthetase; iNOS, inducible NOS.